Status:
COMPLETED
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction
Lead Sponsor:
Fudan University
Conditions:
Pancreatic Tumor, Benign
Pancreatic Neuroendocrine Tumor
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The aim of this study is to evaluate the impact of concomitant main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic tumor enucleation on long-term patient prog...
Detailed Description
Standard surgical procedures for benign or low-grade malignant pancreatic tumors is associated with increased risks of postoperative complications and long-term pancreatic functional impairment, while...
Eligibility Criteria
Inclusion
- age between 18 and 75 years, regardless of gender;
- patients with solitary benign or low-grade malignant pancreatic tumors, including NET, SPN, and cystic tumors;
- eligible for pancreatic parenchyma-sparing resection (PSR) according to contemporary guidelines;
- patients with an ECOG performance status of 0 or 1;
- successfully received MIEN (laparoscopic or robotic)
Exclusion
- body mass index \> 35 kg/m2;
- concomitant malignancies;
- intraoperative frozen section or postoperative pathology indicating malignancy, requiring conversion to oncologic resection;
- loss to follow-up within 90 days postoperatively.
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT06024343
Start Date
July 1 2019
End Date
August 31 2024
Last Update
November 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China